Taken together,our study showed the anti-inflammatory effects of IFNL1-expressingprobiotics in two in vitro IBD models, demonstratingtheir potential as live biotherapeutics for IBD immunotherapy. This evidence concerns the gene IFNL1 and inflammatory bowel disease.